Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV
Date:
11/15/2021
Citation:
Ruddy JA, Boyarsky BJ, Bailey JR, Karaba AH, Garonzik-Wang JM, Segev DL, Durand CM, Werbel WA. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. AIDS. 2021 Nov 15;35(14):2399-2401. doi: 10.1097/QAD.0000000000003017. PMID: 34261097.
Abstract
This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.